HK1087108A1 - 5,7-diaminopyrazolo[4,3-d] pyrimidines useful in the treatment of hypertension - Google Patents
5,7-diaminopyrazolo[4,3-d] pyrimidines useful in the treatment of hypertensionInfo
- Publication number
- HK1087108A1 HK1087108A1 HK06107285.3A HK06107285A HK1087108A1 HK 1087108 A1 HK1087108 A1 HK 1087108A1 HK 06107285 A HK06107285 A HK 06107285A HK 1087108 A1 HK1087108 A1 HK 1087108A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diaminopyrazolo
- hypertension
- treatment
- pyrimidines useful
- pyrimidines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0309780 | 2003-04-29 | ||
GBGB0327748.0A GB0327748D0 (en) | 2003-11-28 | 2003-11-28 | Novel pharmaceuticals |
PCT/IB2004/001433 WO2004096810A1 (en) | 2003-04-29 | 2004-04-22 | 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1087108A1 true HK1087108A1 (en) | 2006-10-06 |
Family
ID=33420887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06107285.3A HK1087108A1 (en) | 2003-04-29 | 2006-06-28 | 5,7-diaminopyrazolo[4,3-d] pyrimidines useful in the treatment of hypertension |
Country Status (32)
Country | Link |
---|---|
US (2) | US7262192B2 (no) |
EP (1) | EP1620437B1 (no) |
JP (2) | JP4015176B2 (no) |
KR (1) | KR100824193B1 (no) |
AR (1) | AR044116A1 (no) |
AT (1) | ATE433978T1 (no) |
AU (1) | AU2004234158B2 (no) |
BR (1) | BRPI0409903A (no) |
CA (1) | CA2523831C (no) |
CL (1) | CL2004000889A1 (no) |
CO (1) | CO5640118A2 (no) |
CR (1) | CR8051A (no) |
DE (1) | DE602004021585D1 (no) |
DK (1) | DK1620437T3 (no) |
EA (1) | EA008596B1 (no) |
EC (1) | ECSP056130A (no) |
ES (1) | ES2326119T3 (no) |
GE (1) | GEP20084329B (no) |
HK (1) | HK1087108A1 (no) |
IS (1) | IS8009A (no) |
MA (1) | MA27771A1 (no) |
MX (1) | MXPA05011643A (no) |
NL (1) | NL1026074C2 (no) |
NO (1) | NO333850B1 (no) |
NZ (1) | NZ542097A (no) |
OA (1) | OA13050A (no) |
PA (1) | PA8601701A1 (no) |
PE (1) | PE20050462A1 (no) |
RS (1) | RS20050810A (no) |
TW (1) | TWI273908B (no) |
UY (1) | UY28290A1 (no) |
WO (1) | WO2004096810A1 (no) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
OA13050A (en) | 2003-04-29 | 2006-11-10 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension. |
GB0322552D0 (en) * | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
GB0327319D0 (en) * | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
GB0327323D0 (en) * | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
DE602005011784D1 (de) | 2004-04-07 | 2009-01-29 | Pfizer | Pyrazoloä4,3-düpyrimidine |
CN101083992A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物 |
MX2007003327A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
CA2580787A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
TW200626138A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
AU2005286648A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
AR051092A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa |
EP2269610A3 (en) | 2004-09-20 | 2011-03-09 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
WO2006046135A2 (en) * | 2004-10-28 | 2006-05-04 | Pharmacia & Upjohn Company Llc | Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors |
EP1831216A2 (en) * | 2004-12-23 | 2007-09-12 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
GB0428250D0 (en) * | 2004-12-23 | 2005-01-26 | Novartis Ag | Organic compounds |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP2008540335A (ja) * | 2005-04-27 | 2008-11-20 | アストラゼネカ・アクチエボラーグ | ピラゾリル・ピリミジン誘導体の疼痛治療における使用 |
US8227475B2 (en) * | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
ES2357120T3 (es) * | 2005-05-12 | 2011-04-18 | Pfizer, Inc. | Formas cristalinas anhidra de n-(1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo(4,3-d)pirimidina-3-carbonil)metanosulfonamida. |
CA2618646A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
EP1915377A1 (en) | 2005-07-22 | 2008-04-30 | Sunesis Pharmaceuticals, Inc. | Pyrazolo pyrimidines useful as aurora kinase inhibitors |
WO2007023382A2 (en) * | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
EP1874781B9 (de) * | 2006-04-19 | 2010-09-08 | Boehringer Ingelheim International GmbH | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen |
CA2705414C (en) | 2007-10-19 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Substituted piperidino-dihydrothienopyrimidines |
CA2702518A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | New piperazino-dihydrothienopyrimidine derivatives |
NZ585348A (en) | 2007-10-19 | 2012-02-24 | Boehringer Ingelheim Int | Heterocycle-substituted piperazino-dihydrothienopyrimidines |
NZ587589A (en) | 2008-02-15 | 2012-10-26 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
US8212031B2 (en) * | 2008-03-06 | 2012-07-03 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
WO2009124119A2 (en) * | 2008-04-01 | 2009-10-08 | The Trustes of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
EP2276420B1 (en) | 2008-04-04 | 2021-10-06 | Journey1, Inc. | Device to treat an eye having an epithelium with a defect |
EP2116618A1 (en) * | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
AU2009276420A1 (en) * | 2008-08-01 | 2010-02-04 | Biocryst Pharmaceuticals, Inc. | Piperidine derivatives as JAK3 inhibitors |
CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
ES2649890T3 (es) | 2009-10-23 | 2018-01-16 | Nexisvision, Inc. | Enervación corneal para el tratamiento de dolor ocular |
EP2490620A4 (en) | 2009-10-23 | 2017-03-22 | Forsight Labs, Llc | Conformable therapeutic shield for vision and pain |
EP2710005B1 (en) * | 2011-05-17 | 2016-10-05 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
JO3753B1 (ar) | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
CA2916885A1 (en) | 2013-06-26 | 2014-12-31 | Nexisvision, Inc. | Contact lenses for refractive correction |
ES2779152T3 (es) * | 2013-10-07 | 2020-08-13 | Kadmon Corporation Llc | Derivados de (2-(5-isoindolin-2-il)pirimidin-4-il)-amina como inhibidores de Rho-quinasa para tratar enfermedades autoinmunes |
EA033298B1 (ru) | 2015-03-03 | 2019-09-30 | Саниона А/С | Комбинированная лекарственная форма тезофензина и метопролола |
EP3390402B1 (en) * | 2015-12-18 | 2020-01-15 | H. Hoffnabb-La Roche Ag | Therapeutic compounds, compositions and methods of use thereof |
US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
CN109923114B (zh) | 2016-09-09 | 2022-11-01 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途 |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
CA3063174A1 (en) * | 2017-05-12 | 2018-11-15 | Innovus Pharmaceuticals, Inc. | Therapeutic methods and compositions |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
US10864205B2 (en) | 2017-12-01 | 2020-12-15 | Innovus Pharmaceuticals, Inc. | Nutritional supplement for improving sexual health in men and women |
US10500199B2 (en) | 2017-12-01 | 2019-12-10 | Innovus Pharmaceuticals, Inc. | Nutritional supplement for increasing cognitive functions |
US20190167699A1 (en) | 2017-12-01 | 2019-06-06 | Innovus Pharmaceuticals, Inc. | Prostate function support formula |
US10758505B2 (en) | 2017-12-01 | 2020-09-01 | Innovus Pharmaceuticals, Inc. | Therapeutic compositions and methods |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
LT3755703T (lt) | 2018-02-20 | 2022-10-10 | Incyte Corporation | N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
EP3856348B1 (en) | 2018-09-25 | 2024-01-03 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators |
PE20221419A1 (es) | 2019-08-06 | 2022-09-20 | Incyte Corp | Formas solidas de un inhibidor de hpk1 |
WO2022012409A1 (zh) * | 2020-07-14 | 2022-01-20 | 武汉朗来科技发展有限公司 | 一种rock抑制剂及其制备方法和用途 |
WO2024105159A1 (en) | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3951980A (en) | 1974-05-09 | 1976-04-20 | Stanford Research Institute | 3-Substituted-8-methyl-3,8-diazabicyclo[3.2.1]octanes |
AU516604B2 (en) | 1978-04-03 | 1981-06-11 | Yoshida Kogyo K.K. | Tiltable roller assembly |
ATE171185T1 (de) | 1985-03-15 | 1998-10-15 | Antivirals Inc | Immunotestmittel für polynukleotid und verfahren |
US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
US4812590A (en) | 1987-06-25 | 1989-03-14 | Merck & Co., Inc. | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma |
WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
GB8728483D0 (en) | 1987-12-04 | 1988-01-13 | Ciba Geigy Ag | Chemical compounds |
US5091431A (en) * | 1988-02-08 | 1992-02-25 | Schering Corporation | Phosphodiesterase inhibitors |
US5075310A (en) | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
FR2638745B1 (fr) | 1988-11-08 | 1994-01-14 | Synthelabo | Derives de ((n-alkylthioalkyl-methylamino)-2 ethyl)-5 benzothiazepine-1,5 one-4, leur preparation et leur application en therapeutique |
US4994460A (en) | 1989-06-01 | 1991-02-19 | Bristol-Myers Squibb Co. | Agents for treatment of brain ischemia |
JPH03142277A (ja) | 1989-10-30 | 1991-06-18 | Fuji Photo Film Co Ltd | 記録材料 |
US5442044A (en) | 1991-01-04 | 1995-08-15 | Pfizer Inc. | Orally active renin inhibitors |
AU653855B2 (en) | 1991-07-03 | 1994-10-13 | Pharmacia & Upjohn Company | Indolyl carbonyl pyridinyl-poperazine/piperidine derivatives |
GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
JP2657760B2 (ja) | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | 4−アミノキナゾリン誘導体およびそれを含有する医薬品 |
GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
US5869486A (en) | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
WO1996028448A1 (en) | 1995-03-10 | 1996-09-19 | Sanofi Winthrop, Inc. | 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
AU735401B2 (en) | 1996-08-28 | 2001-07-05 | Pfizer Inc. | Substituted 6,5-hetero-bicyclic derivatives |
DE19644228A1 (de) | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine |
NZ338075A (en) | 1997-04-25 | 2000-10-27 | Pfizer Ltd | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction |
US6184338B1 (en) | 1997-08-27 | 2001-02-06 | Fmc Corporation | Anionic polymerization initiators containing tertiary amine functionality, their chain extended analogues, and processes for using the same |
EP2295436A1 (de) | 1997-11-12 | 2011-03-16 | Bayer Schering Pharma AG | 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren |
DE19752952A1 (de) | 1997-11-28 | 1999-06-02 | Merck Patent Gmbh | Thienopyrimidine |
CA2260499A1 (en) | 1998-01-29 | 1999-07-29 | Sumitomo Pharmaceuticals Company Limited | Pharmaceutical compositions for the treatment of ischemic brain damage |
GB9804426D0 (en) | 1998-03-02 | 1998-04-29 | Pfizer Ltd | Heterocycles |
CA2329077C (en) | 1998-04-20 | 2007-09-18 | Pfizer Inc. | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
CA2347950C (en) | 1998-10-23 | 2005-05-03 | Pfizer Inc. | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
JP2002538208A (ja) | 1999-03-10 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬としての6−アザインドール化合物 |
US6465486B1 (en) | 1999-03-12 | 2002-10-15 | Ortho-Mcneil Pharmaceutical, Inc. | Pyridyl/quinolinyl imidazoles |
GB9912415D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
DE19942474A1 (de) | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
WO2001023389A2 (en) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
YU23602A (sh) | 1999-09-30 | 2004-09-03 | Neurogen Corporation | Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini |
CZ20021067A3 (cs) | 1999-09-30 | 2002-11-13 | Neurogen Corporation | Určité alkylendiaminové substituované pyrazolo[1,5-a]- 1,5-pyrimidiny a pyrazolo[1,5-a]-1,3,5-triaziny |
CN1378547A (zh) | 1999-10-11 | 2002-11-06 | 辉瑞大药厂 | 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4,3-d]嘧啶-7-酮类化合物 |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
US6548509B2 (en) | 1999-10-22 | 2003-04-15 | Neurogen Corporation | 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
GB9930570D0 (en) | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
AU784340B2 (en) | 1999-12-23 | 2006-03-16 | Pfizer Products Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
CZ20022353A3 (cs) | 2000-01-07 | 2003-02-12 | Universitaire Instelling Antwerpen | Deriváty purinu, způsob jejich přípravy a jejich použití |
US20010047013A1 (en) | 2000-03-10 | 2001-11-29 | Fengrui Lang | Process for the preparation of arylamines |
DE10031584A1 (de) | 2000-06-29 | 2002-01-10 | Merck Patent Gmbh | 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine |
EP1176142A1 (en) | 2000-07-28 | 2002-01-30 | Pfizer Inc. | Process for the preparation of pyrazoles |
DZ3364A1 (fr) | 2000-07-28 | 2002-02-07 | Pfizer | Agent therapeutique cristallin |
EP1176147A1 (en) | 2000-07-28 | 2002-01-30 | Pfizer Limited | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof |
IL154158A0 (en) | 2000-08-11 | 2003-07-31 | Pfizer | Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
EP1341782A2 (en) | 2000-11-20 | 2003-09-10 | Scios Inc. | Inhibitors of p38 kinase |
DE10058662A1 (de) | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Pyrazolo[4,3-d]pyrimidinen |
MXPA03005393A (es) | 2000-12-19 | 2003-09-25 | Merck Patent Gmbh | Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina. |
DE10104095A1 (de) | 2001-01-31 | 2002-08-01 | Merck Patent Gmbh | Pharmazeutische Formulierung enthaltend Pyrazolo [4,3-d]pyrimidine und Nitrate |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
JP2002255932A (ja) | 2001-03-01 | 2002-09-11 | Katayama Seiyakushiyo:Kk | 3−アルキルアミノアゼチジンの製造方法 |
US20020127593A1 (en) | 2001-03-12 | 2002-09-12 | Regents Of The University Of California | Fluorescence assay for DNA modifying enzymes |
GB0106631D0 (en) | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
US6432957B1 (en) | 2001-06-29 | 2002-08-13 | Kowa Co., Ltd. | Piperazine derivative |
AU2003276824B8 (en) | 2002-03-15 | 2009-01-22 | The Regents Of The University Of Michigan | Novel 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purines as antiviral agents |
DK1348707T3 (da) | 2002-03-28 | 2010-12-13 | Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro | Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse |
US7505971B2 (en) | 2002-06-28 | 2009-03-17 | Hewlett-Packard Development Company, L.P. | Shared drive that provides shared access to editable files in a database |
OA13050A (en) | 2003-04-29 | 2006-11-10 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension. |
-
2004
- 2004-04-22 OA OA1200500306A patent/OA13050A/en unknown
- 2004-04-22 DK DK04728868T patent/DK1620437T3/da active
- 2004-04-22 RS YUP-2005/0810A patent/RS20050810A/sr unknown
- 2004-04-22 NZ NZ542097A patent/NZ542097A/en unknown
- 2004-04-22 AT AT04728868T patent/ATE433978T1/de not_active IP Right Cessation
- 2004-04-22 WO PCT/IB2004/001433 patent/WO2004096810A1/en active Application Filing
- 2004-04-22 AU AU2004234158A patent/AU2004234158B2/en not_active Ceased
- 2004-04-22 ES ES04728868T patent/ES2326119T3/es not_active Expired - Lifetime
- 2004-04-22 KR KR1020057020497A patent/KR100824193B1/ko not_active IP Right Cessation
- 2004-04-22 GE GEAP20049033A patent/GEP20084329B/en unknown
- 2004-04-22 MX MXPA05011643A patent/MXPA05011643A/es active IP Right Grant
- 2004-04-22 JP JP2006500346A patent/JP4015176B2/ja not_active Expired - Fee Related
- 2004-04-22 EA EA200501333A patent/EA008596B1/ru not_active IP Right Cessation
- 2004-04-22 BR BRPI0409903-6A patent/BRPI0409903A/pt not_active IP Right Cessation
- 2004-04-22 EP EP04728868A patent/EP1620437B1/en not_active Expired - Lifetime
- 2004-04-22 CA CA002523831A patent/CA2523831C/en not_active Expired - Lifetime
- 2004-04-22 DE DE602004021585T patent/DE602004021585D1/de not_active Expired - Lifetime
- 2004-04-26 PE PE2004000411A patent/PE20050462A1/es not_active Application Discontinuation
- 2004-04-27 UY UY28290A patent/UY28290A1/es not_active Application Discontinuation
- 2004-04-27 CL CL200400889A patent/CL2004000889A1/es unknown
- 2004-04-28 TW TW093111926A patent/TWI273908B/zh not_active IP Right Cessation
- 2004-04-28 NL NL1026074A patent/NL1026074C2/nl not_active IP Right Cessation
- 2004-04-28 AR ARP040101440A patent/AR044116A1/es unknown
- 2004-04-29 PA PA20048601701A patent/PA8601701A1/es unknown
- 2004-04-29 US US10/834,484 patent/US7262192B2/en not_active Expired - Fee Related
-
2005
- 2005-08-31 IS IS8009A patent/IS8009A/is unknown
- 2005-09-22 NO NO20054404A patent/NO333850B1/no not_active IP Right Cessation
- 2005-10-20 CR CR8051A patent/CR8051A/es not_active Application Discontinuation
- 2005-10-28 MA MA28571A patent/MA27771A1/fr unknown
- 2005-10-28 CO CO05110249A patent/CO5640118A2/es not_active Application Discontinuation
- 2005-10-28 EC EC2005006130A patent/ECSP056130A/es unknown
-
2006
- 2006-06-28 HK HK06107285.3A patent/HK1087108A1/xx not_active IP Right Cessation
-
2007
- 2007-03-16 JP JP2007067736A patent/JP2007217419A/ja active Pending
- 2007-07-31 US US11/831,021 patent/US20070270412A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1087108A1 (en) | 5,7-diaminopyrazolo[4,3-d] pyrimidines useful in the treatment of hypertension | |
AU2003209594A1 (en) | Quinazoline compounds useful in therapy | |
IL168102A0 (en) | Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | |
HK1086012A1 (en) | 8-substitued-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives | |
EP1599482A4 (en) | PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES | |
IL187528A0 (en) | Use of pyrimidine compounds in the manufacture of medicaments | |
SI1487805T1 (sl) | Pirimidinski derivati | |
EP1546115A4 (en) | SUBSTITUTED PYRIMIDINES | |
IL182099A0 (en) | Piperidinylamino-thieno[2,3-d] pyrimidine compounds | |
HK1091488A1 (en) | Pyrimidine derivatives | |
IL166100A0 (en) | 7,8,9-10-tetrahydro-6h-azepino,6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrroloÄ2,1-bÜ quinazolinone derivatives | |
HK1088893A1 (en) | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives | |
AU2003212634A8 (en) | Compounds useful in the treatment of cancer | |
EP1611147A4 (en) | 6 "amino-6" -DEOXYGALACTOSYLCERAMIDE | |
IL169318A0 (en) | Pyrimidines, methods for the production thereof, and use thereof | |
EP1363637A4 (en) | PYRIMIDINE COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
GB0323137D0 (en) | 2,4,6- Trisubstituted pyrimidines and their different uses | |
SG150544A1 (en) | Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivatives, their manufacture and use as pharmaceutical agents | |
AP2005003429A0 (en) | 5,7-Diaminopyrazolo Ä4,3-DÜ pyrimidines useful in the treatment of hypertension. | |
IL173347A0 (en) | 7-SUBSTITUTED 3-NITRO-PYRAZOLO[1,5-a] PYRIMIDINES | |
GB0227443D0 (en) | Pyrimidine derivatives | |
TJ20020735A (en) | 2-bROM-7-METHIL-5-OXO-5H-1,3,4-thyodyazol Ä3,2-AÜ pyrimidin | |
GB0318162D0 (en) | Polishes and their uses | |
HUS1400055I1 (hu) | Rák kezelésére alkalmas 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2H-pirido[2,3-d]pirimidin-származékok és rokon vegyületek | |
GB0312869D0 (en) | Improvements in or relating to rucksacks or the like |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160422 |